HAVCR2 and acute myeloid leukemia: In addition to CTLA-4 and PD-1/PD-L1, numbers of clinical trials of TIM-3 inhibitors including sabatolimab and TQB2618 for AML are recruiting patients (NCT05426798, NCT03940352, NCT04623216, NCT05367401, NCT03066648).